Pharmacological profile of ALKS 7119, an investigational compound evaluated for the treatment of neuropsychiatric disorders, in healthy volunteers

Aims ALKS 7119 is a novel compound with in vitro affinity highest for the SERT, and for μ receptor, α1A‐adrenoceptor, α1B‐adrenoceptor, NMDA receptor and sigma non‐opioid intracellular receptor 1. This first‐in‐human study evaluated safety and PK/PD effects of single ascending doses (SAD) of ALKS 71...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2022-06, Vol.88 (6), p.2909-2925
Main Authors: Dijkstra, Francis M., Zuiker, Rob G. J. A., Siebenga, Pieter S., Leigh‐Pemberton, Richard A., Sun, Lei, Manthis, Joan D., Kam, Marieke L., Lin, Richard, Moltke, Lisa L., Rezendes, David, Gerven, Joop M. A.
Format: Article
Language:English
Subjects:
Dose-Response Relationship, Drug
Double-Blind Method
drug development
Healthy Volunteers
Humans
Hydrocortisone
Male
neuropsychiatric disorders
Original
pharmacological effects
Prolactin
Receptors, Adrenergic
Saccades
SERT
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Aims ALKS 7119 is a novel compound with in vitro affinity highest for the SERT, and for μ receptor, α1A‐adrenoceptor, α1B‐adrenoceptor, NMDA receptor and sigma non‐opioid intracellular receptor 1. This first‐in‐human study evaluated safety and PK/PD effects of single ascending doses (SAD) of ALKS 7119 in healthy males and compared effects with neurotransmitter modulators with partially overlapping targets. Methods In 10 cohorts (n = 10 subjects each), PK, safety and PD (NeuroCart tests, measuring neurophysiologic effects [pupillometry, pharmaco‐EEG (pEEG)], visuomotor coordination, alertness, [sustained] attention [saccadic peak velocity, adaptive tracking], subjective drug effects [VAS Bowdle and VAS Bond and Lader] and postural stability [body sway]) were evaluated. Neuroendocrine effects (cortisol, prolactin, growth hormone) were measured. Data were analysed over the 12‐hour post‐dose period using mixed‐effects model for repeated measure (MMRM) with baseline as covariate. Results ALKS 7119 demonstrated linear PK and was generally well tolerated. QTcF interval increases of 30–60 ms compared to baseline were observed with ALKS 7119 doses of ≥50 mg without related adverse events. Significant increases in left and right pupil/iris ratio were observed at dose levels ≥50 mg (estimate of difference [95% CI], P‐value) (0.04 [0.01; 0.07], P 
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.15229